MaxCyte Inc's (LON:MXCT) Doug Doerfler talks Proactive London's Andrew Scott through a licensing deal they've signed with a company developing the next wave of cancer immunotherapies.
Allogene Therapeutics Inc (NASDAQ:ALLO) will use MaxCyte’s Flow Electroporation platform and ExPERT technology to “develop and advance” its allogeneic CAR T treatments.